Quantbot Technologies LP Has $11.51 Million Stock Position in McKesson Co. (NYSE:MCK)

Quantbot Technologies LP raised its position in shares of McKesson Co. (NYSE:MCK) by 60.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,201 shares of the company’s stock after purchasing an additional 7,638 shares during the quarter. McKesson accounts for 0.4% of Quantbot Technologies LP’s investment portfolio, making the stock its 27th biggest holding. Quantbot Technologies LP’s holdings in McKesson were worth $11,513,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Thrivent Financial for Lutherans lifted its position in shares of McKesson by 5.8% in the third quarter. Thrivent Financial for Lutherans now owns 20,142 shares of the company’s stock worth $9,964,000 after buying an additional 1,106 shares during the last quarter. Prospera Financial Services Inc increased its position in shares of McKesson by 5.5% during the third quarter. Prospera Financial Services Inc now owns 2,559 shares of the company’s stock valued at $1,267,000 after purchasing an additional 133 shares during the period. Fifth Third Wealth Advisors LLC lifted its holdings in shares of McKesson by 5.2% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 722 shares of the company’s stock worth $357,000 after acquiring an additional 36 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in McKesson during the third quarter worth about $2,148,000. Finally, Advisors Asset Management Inc. boosted its stake in McKesson by 2.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 11,471 shares of the company’s stock valued at $5,671,000 after buying an additional 319 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Price Performance

Shares of MCK stock opened at $659.45 on Friday. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $670.79. The company’s fifty day simple moving average is $616.14 and its two-hundred day simple moving average is $574.33. The stock has a market capitalization of $82.65 billion, a price-to-earnings ratio of 30.19, a PEG ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Equities research analysts anticipate that McKesson Co. will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. The ex-dividend date is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.43%. McKesson’s payout ratio is currently 13.00%.

Analyst Ratings Changes

A number of brokerages have weighed in on MCK. Morgan Stanley boosted their target price on shares of McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Mizuho assumed coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 target price for the company. Citigroup decreased their price objective on McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a research report on Friday, January 10th. StockNews.com lowered McKesson from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company raised their target price on shares of McKesson from $641.00 to $691.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and an average price target of $649.36.

Insider Buying and Selling

In related news, EVP Leann B. Smith sold 188 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total transaction of $114,602.92. Following the sale, the executive vice president now directly owns 1,051 shares of the company’s stock, valued at approximately $640,679.09. This represents a 15.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 8,961 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the transaction, the chief executive officer now owns 60,664 shares of the company’s stock, valued at $36,276,465.36. This represents a 12.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,689 shares of company stock valued at $11,187,351 over the last ninety days. 0.11% of the stock is owned by insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.